NCT01927159已完成1 期
A Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of the ID93 + GLA-SE Vaccine in BCG-Vaccinated Healthy Adults
Access to Advanced Health Institute (AAHI)2 个研究点 分布在 1 个国家目标入组 66 人开始时间: 2013年9月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 66
- 试验地点
- 2
- 主要终点
- Number of Adverse Events
研究概览
简要总结
The purpose of this study is to determine the safety, tolerability, and immunogenicity in BCG-vaccinated healthy adult subjects of an investigational vaccine being developed for the prevention of pulmonary tuberculosis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Has completed the written informed consent process prior to start of screening evaluations
- •Male or female who is ≥18 years and ≤50 years of age at the time of randomization
- •Agrees to stay in contact with the study site for the duration of the study, provide updated contact information as necessary, and has no current plans to move from the study area for the duration of the study
- •Agrees to avoid elective surgery for the full duration of the study
- •For female participants: agrees to avoid pregnancy from 21 days prior to Study Day 0 and for the full duration of the study. Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses if menopausal) in sexual relationships with men must use an acceptable method of avoiding pregnancy during this period. Acceptable methods of avoiding pregnancy include a sterile sexual partner, sexual abstinence(not engaging in sexual intercourse), hormonal contraceptives (oral, injection, transdermal patch, or implant), vaginal ring, intrauterine device (IUD), or the combination of a condom or diaphragm with spermicide gel
- •Has general good health, confirmed by medical history and physical examination
- •Has body mass index (BMI) between 19 and 33 (weight/height2) by nomogram
- •Had BCG vaccination at least 5 years ago, documented through medical history or presence of scar
排除标准
- •Acute illness at the time of randomization
- •Oral temperature ≥37.5°C at the time of randomization
- •Clinically significant abnormal laboratory values for any of the following screening laboratory parameters, per local laboratory normal ranges from blood collected within 30 days prior to Study Day 0 randomization as follows:
- •hemoglobin, hematocrit, absolute neutrophil count, absolute lymphocyte count, or platelet count below lower limit of normal (LLN)
- •white blood cell count above upper limit of normal (ULN) or below LLN (i.e., must be within normal limits)
- •ALT, AST, total bilirubin, alkaline phosphatase, creatinine, or blood urea nitrogen (BUN) above ULN
- •Evidence of systemic or local disease process on screening urinalysis
- •Evidence of significant active infection
- •History of treatment for active or latent tuberculosis or evidence of active tuberculosis
- •Shared a residence within the last year prior to randomization with an individual on anti-tuberculosis treatment or with culture or smear positive tuberculosis
- •History of autoimmune disease or immunosuppression
- •Used immunosuppressive medication within 42 days before randomization (inhaled and topical corticosteroids are permitted)
- •Received immunoglobulin or blood products within 42 days before randomization
- •Received any investigational drug therapy or investigational vaccine within 182 days before randomization, or planned participation in any other investigational study during the study period
- •Received investigational Mtb vaccine at any time prior to randomization
- •Received a live vaccine within past 4 weeks or a killed vaccine within past 2 weeks prior to randomization.
- •Unable to discontinue current chronic prescription drug therapy that can be hepatotoxic or toxic to the bone marrow or kidneys.
- •History or laboratory evidence of immunodeficiency state including but not limited to any laboratory indication of HIV-1 infection
- •History of allergic disease or reactions (including allergy to kanamycin-related antibiotics, allergic reaction to eggs, and severe eczema), likely to be exacerbated by any component of the study vaccine
- •Previous medical history that may compromise the safety of the participant in the study, including but not limited to: severe impairment of pulmonary function from pulmonary disease; chronic illness with signs of cardiac or renal failure; suspected progressive neurological disease; or uncontrolled epilepsy
- •Evidence of chronic hepatitis (e.g., hepatitis B surface antigen or hepatitis C antibody)
- •Chronic heavy ethanol intake which, in the opinion of the investigator, may compromise the safety of the participant or interfere with the evaluation of the safety of the vaccine
- •Cannabis smoking 3 or more days per week
- •Positive urine test for illicit drugs (opiates, cocaine, amphetamines)
- •History or evidence on physical examination of any systemic disease or any acute or chronic illness that, in the opinion of the investigator, may interfere with the evaluation of the safety or immunogenicity of the vaccine
- •All female participants: currently pregnant or lactating/nursing; or positive urine pregnancy test during screening or on the day of study injection
- •Received a tuberculin skin test within 3 months (90 days) prior to Study Day 0
- •Any current medical, psychiatric, occupational, or substance abuse problems that, in the opinion of the investigator, will make it unlikely that the participant will comply with the protocol or may compromise the safety of the participant
研究组 & 干预措施
10 mcg ID93 + 2 mcg GLA-SE Vaccine
Experimental
Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. High dose of antigen and low dose of adjuvant.
干预措施: ID93 + GLA-SE (Biological)
2 mcg ID93 + 2 mcg GLA-SE Vaccine
Experimental
Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. Low dose of antigen and low dose of adjuvant.
干预措施: ID93 + GLA-SE (Biological)
Saline
Placebo Comparator
Three intramuscular injections of saline at Days 0, 28, and 112.
干预措施: Placebo (Other)
10 mcg ID93 + 2 mcg GLA-SE Vaccine (QFT-)
Experimental
Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. High dose of antigen and low dose of adjuvant. This group limited to adults with negative Quantiferon Gold TB (QFT) test.
干预措施: ID93 + GLA-SE (Biological)
10 mcg ID93 + 5 mcg GLA-SE Vaccine
Experimental
Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. High dose of antigen and high dose of adjuvant.
干预措施: ID93 + GLA-SE (Biological)
结局指标
主要结局
Number of Adverse Events
时间窗: 294 days
Solicited and unsolicited adverse events will be recorded for 28 days following each study injection; serious adverse events and adverse events of special interest will be recorded for the duration of the study.
次要结局
- Immunogenicity(Days 0, 14, 42, 112, 126, 196, 294)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Safety and Immunogenicity Study of tgAAC09, a Gag-PR-RT AAV HIV VaccineHIV InfectionNCT00482027International AIDS Vaccine Initiative80
终止
2 期
Bacille Calmette Guerin (BCG) Revaccination of Healthy Adolescents for the Prevention of Mycobacterium Tuberculosis Sustained InfectionTuberculosisNCT04152161Bill & Melinda Gates Medical Research Institute1,836
已完成
1 期
Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 VaccineStaphylococcal InfectionsYeast InfectionsCandidiasisNCT01447407NovaDigm Therapeutics, Inc.164
进行中（未招募）
不适用
BCG vaccination against COVID-19CTRI/2020/06/025854Indian Council of Medical Research
已完成
1 期
Chiron Corp HCV E1/E2 VaccineHepatitis CNCT00500747National Institute of Allergy and Infectious Diseases (NIAID)60